What is it about?
This paper reports the results of a clinical study that tested the natural Gene-Eden-VIR/Novirin in genital herpes. The study showed that Gene Eden-VIR/Novirin safely and effectively decreases the number of genital herpes outbreaks. The study also showed that Gene-Eden-VIR/Novirin is more effective and safer than the leading drugs Acyclovir (Zovirax) and Valacyclovir (Valtrex and Zelitrex), sold by GlaxoSmithKline (NYSE:GSK), and Famciclovir (Famvir), sold by Novartis (NYSE:NVS). The study was published in the peer reviewed medical journal Drug Design, Development and therapy. Gene-Eden-VIR/Novirin is a patented botanical product that consists of five natural ingredients, quercetin, green tea extract, cinnamon extract, licorice extract, and selenium. The product was developed to target latent viruses, and weaken their effect on the host. Gene-Eden-VIR/Novirin was introduced in the marketplace at the end of 2009. A previous clinical study showed that Gene-Eden-VIR/Novirin is antiviral. The scientists, who developed Gene-Eden-VIR, used a unique scientific tool, Computer Intuition, a proprietary psycholinguistic-based, data-mining program that analyzes scientific text. The scientists’ objective was to identify natural ingredients mentioned in the scientific literature that have a strong antiviral effect against the most common viruses. To achieve the objective, they used Computer Intuition to analyze more than 50,000 pa pers. Using the Computer Intuition results, they created the Gene-Eden-VIR/Novirin formula.
Featured Image
Why is it important?
The paper is important for a few reasons: 1. It introduces a new antiviral treatment in more than 20 years. 2. It shows that the new antiviral treatment is safer and more effective than the leading drugs in the category. 3. It introduces a natural alternative to antiviral drugs.
Perspectives
Read the Original
This page is a summary of: Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir, Drug Design Development and Therapy, August 2016, Dove Medical Press,
DOI: 10.2147/dddt.s112852.
You can read the full text:
Resources
Contributors
The following have contributed to this page